Document is current
Any future updates will be listed below
-
Authors
Stelten, Bianca M. L. https://orcid.org/0000-0003-0237-1406
Dotti, Maria Teresa
Verrips, Aad
Elibol, Bülent
Falik-Zaccai, Tzipora C.
Hanman, Kate
Mignarri, Andrea
Sithole, Belina
Steiner, Robert D.
Verma, Surabhi
Yahalom, Gilad
Zubarioglu, Tanyel
Mochel, Fanny
Federico, Antonio
-
Funding
Funding for this research was provided by:
Leadiant Biosciences
- License Information
-
More Information
Article History
Received: 1 March 2021
Accepted: 25 July 2021
First Online: 6 August 2021
Declarations
:
: Not applicable.
: Not applicable.
: AF: Received a grant from Leadiant Biosciences. Member of HCT of European Reference Network on Rare Neurologic Diseases. AM: Member of HCT of European Reference Network on Rare Neurologic Diseases. AV: Receives honoraria from serving as a consultant for Leadiant Biosciences, Inc. (USA) and Leadiant Biosciences Ltd (UK). BE: Received honorarium from THParm as advisory board member. BSi: Employee of Costello Medical. BSt: None to declare. FM: Previously received an education grant from Leadiant Biosciences. GY: Received consultation fees from Abbvie Inc. KH: Employee of Costello Medical. MTD: Received a grant from Leadiant Biosciences. Member of HCT of European Reference Network on Rare Neurologic Diseases. RDS: Served as a paid consultant to Retrophin. He held or holds patents related to newborn screening for sterol and bile acid disorders which are not licensed and for which there are no resulting royalties. He is an employee of PreventionGenetics which offers fee based genetic testing for CTX. SV: Employee of Leadiant Biosciences. TZ: None to declare. TCF-Z: None to declare.
